The Intellectual Property Owners Association (IPO) will offer two one-hour webinars on February 20 and 26, 2020. In the first webinar, entitled "Blocking Patents in Litigation after Acorda: What's Acorda's Impact Inside and Outside of Pharma?" which will be held on February 20, 2020 from 2:00 to 3:00 pm (ET), Elaine Blais of Goodwin Procter, David Manspeizer of Squire Patton Boggs, and Frank Nuzzi of Siemens will analyze whether the Federal Circuit's decision in Acorda v. Roxane is a game changer in Hatch-Waxman litigation; whether the lesser role of secondary considerations will relegate Acorda to the sidelines in high tech patent litigation; and how the fact-specific inquiry required by Acorda will likely play out with discovery, expert testimony, and questions about the burden of proof. In the second webinar, entitled "Blocking Patents in Prosecution Strategy and Corporate IP Strategy after Acorda," which will be held on February 26, 2020 from 2:00 to 3:00 pm (ET), Adriana Burgy of Finnegan, Stephen Durant of Schwegman Lundberg & Woessner, and Jeffrey Hohenshell of Medtronic will discuss what prosecution strategies will best protect such inventions if they are now more vulnerable, and whether such considerations should now impact corporate IP strategy and budgets.
The registration fee for each webinar is $135 (government and academic rates are available upon request). Those interested in registering for either webinar can do so here and here.
Comments